Annual Report 2025

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2025 89 The United Laboratories International Holdings Limited Annual Report 2025 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information Amounts included in the measurement of segment profit or loss: For the year ended 31 December 2025 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,925 – 17,039 – 18,964 Depreciation of right-of-use assets 3,756 8,114 3,652 1,852 17,374 Depreciation of property, plant and equipment 380,645 93,137 137,560 1,863 613,205 Net loss on disposal of property, plant and equipment (14,182) (13,027) 6,173 – (21,036) Written off of property, plant and equipment 39,444 3,421 5,720 – 48,585 Write-down of inventories (reversed) recognised (32,562) 16,562 3,618 – (12,382) Impairment losses (reversed) recognised (3,783) 29,781 (7,375) 1,620 20,243